The Potential of Alpiniae Oxyphyllae Fructus as a Therapeutic Agent for Irritable Bowel Syndrome: In Silico and In Vivo Evidence
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCI
- 저널 순위
- KCI Q3
- 저널
- 생명과학회지35(6) · pp.493 · 2025
- 피인용
- KCI 0
- ISSN
- 1225-9918
저자
초록
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by symptoms such as abdominal pain, altered bowel habits, and inflammation. Alpiniae Oxyphyllae Fructus (AOF), a traditional herbal medicine, has demonstrated anti-inflammatory and gut-regulatory potential. This study aimed to investigate the therapeutic effects of AOF extract on IBS and to identify its active compounds, target genes, and mechanisms of action using network pharmacology, docking analysis, and in vivo experiments. Active compounds and target genes were identified using the TCMSP, TCMBank, and ETCM databases. Gene-disease networks were constructed with Cytoscape, and molecular docking simulations were performed using AutoDock Vina to predict the binding affinity between key compounds and IBS-related targets. A total of 45 active compounds and 239 target genes of AOF were identified, of which 13 targets overlapped with IBS-related genes. GPBAR1, NR1H4, and TNF were highlighted as key targets through network analysis. Docking studies revealed seven active compounds with strong binding affinity (-6 kcal/mol or lower) for GPBAR1, NR1H4, and TNF. In an IBS mouse model, the AOF extract significantly restored colon length, reduced colon weight, and improved stool scores, suggesting a protective effect against zymosan-induced colon damage. These findings provide compelling evidence that AOF and its active compounds modulate the key molecular pathways involved in IBS, making it a promising candidate for IBS treatment.
키워드
Alpiniae oxyphyllae fructusdocking analysisirritable bowel syndromenetwork pharmacologyzymosan
식별자
- KCI
- ART003212519



로그인
연구물 목록으로